Search
for
Sort by
Research 61–90 of 228
- Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
- Ocular Cosmetics in Modern Times
- Drug eruptions in dermatology
- Madarosis, milphosis, eyelash trichomegaly, and dermatochalasis
- Diseases of Periocular Hair
- Malignant epithelial tumors: Part II. Therapy and prevention
- Unilateral Straight Hair—A Symptom of Acquired Horner's Syndrome in a Neonate
- Cutaneous Side Effects of Chemotherapy and Radiotherapy
- Hydroxychloroquine modulates the progression of experimentally induced benign prostatic hyperplasia in rats via targeting EGFR/ERK/STAT3 and AR/FOXO1/TRAIL pathways: computational and in vivo studies
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- Adult Acne
- Cutaneous drug reactions
- Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!
- Research progress on mechanisms of skin aging and anti-aging strategies
- Real-world pharmacovigilance insights into drug-induced risk of alopecia
- Serum irisin level in patients with acne vulgaris
- A Simple Decision Tree Suited for Identification of Early Oral Drug Candidates With Likely Pharmacokinetic Nonlinearity by Intestinal CYP3A Saturation
- Periungual lesions secondary to chemotherapy with docetaxel
- Hair Changes due to Drugs
- Alopecia and drugs
- Index
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
- EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
- Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
- Finasteride
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
- Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
- Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy